Needham analyst John Todaro initiated coverage on TeraWulf Inc (WULF) with a Buy rating and a $6 price target, citing the company’s potential in the high-margin High-Performance Computing (HPC) market. Todaro believes TeraWulf is well-positioned to capitalize on this growing market with its existing data center infrastructure and plans to bring a 100MW+ site online for HPC. He expects TeraWulf to generate significant revenue from HPC in the coming years, leading to attractive margins.
Needham analyst initiated coverage on TransMedics Group (TMDX), a medical technology company revolutionizing organ transplantation with its Organ Care System (OCS). The analyst sees significant growth potential in the underpenetrated organ transplant market, driven by the company’s National OCS Program (NOP) and innovative OCS technology. The analyst predicts TransMedics will become profitable in 2024 and sees rapid improvement in operating margin, EPS, and cash flow in 2025-2026.
